Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor-Reference-Cited by-同舟云学术

Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor

Published:2023-11-02 Issue:1 Volume:388 Page:156-170
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Cai Yu^ORCID,He Jianlin,Wu Zhipeng,He Weigang,Dai Xiaoming,Xu Yan,Cheng Min,Yang Na,Ren Yongxin,Wang Guanglin,Wang Jian,Sai Yang,Jia Hong,Dai Guangxiu,Li Xiong,Su Weiguo

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference35 articles.

1. Syk Tyrosine Kinase Is Critical for B Cell Antibody Responses and Memory B Cell Survival

2. Safety and Efficacy of Tyrosine Kinase Inhibitors in Immune Thrombocytopenic Purpura: A Systematic Review of Clinical Trials;Ali;J Xenobiot,2023

3. VEGF kinase inhibitors: how do they cause hypertension?

4. R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation

5. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sovleplenib in immune thrombocytopenia;The Lancet Haematology;2024-08

2. Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study;The Lancet Haematology;2024-08

3. Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers;ACS Medicinal Chemistry Letters;2024-04-18

4. Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors;Haematologica;2024-01-18